Labcorp (LH) Proxy Filing summary

Executive summary

• Achieved $13.0B in 2024 revenue, with strong performance in diagnostics and biopharma services.

• Introduced innovative specialty tests in oncology, women's health, autoimmunology, and neurology.

• Closed or signed 10 strategic transactions, including acquisition of Invitae assets to expand genetic testing.

• Focused on digital enablement, AI, and global expansion to drive future growth.

Voting matters and shareholder proposals

• Election of ten directors.

• Advisory vote on executive compensation (say-on-pay).

• Approval of 2025 Omnibus Incentive Plan.

• Approval of 2025 Employee Stock Purchase Plan.

• Ratification of Deloitte & Touche LLP as independent auditor for 2025.

Board of directors and corporate governance

• Board is 90% independent, with 60% diversity (gender/ethnic/racial).

• Annual board refreshment and self-assessment; new Lead Independent Director in 2023.

• Proxy access and majority voting in uncontested elections.

• Active shareholder engagement, with over 80% of shares represented in discussions.